• Flanders Investment & Trade
  • Team Vesalius

Piet Wigerinck, Ph.D., joined Galapagos NV in April 2008 as SVP Development and was appointed Chief Scientific Officer in 2010.

Piet Wigerinck


Generaal De Wittelaan L11 A3
2800 Mechelen

Under his leadership, Galapagos has developed a large pipeline of novel mechanism of action drugs; Jyseleca was approved for rheumatoid arthritis in 2020 in the EU and Japan. He has supervised multiple successful proofs-of-concept patient studies, including filgotinib and ziritaxestat.

Prior to his tenure at Galapagos, Piet Wigerinck was Vice President, Drug Discovery, Early Development and CM&C at Tibotec-Virco Comm. VA (a subsidiary of Johnson & Johnson Services, Inc.). Under his leadership at Tibotec Prezista™, Olysio™, and Rekambys™ were selected, moved forward into clinical trials and later approved. Piet Wigerinck has over 30 years of R&D experience in the pharmaceutical industry and biotechnology. He holds a Ph.D. from the K.U. Leuven and is inventor on more than 25 patent applications. In May 2018, he was elected an independent board member of French pharmaceutical company Ipsen SA.

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?